CO2019007888A2 - Inhibidores selectivos de jak1 - Google Patents

Inhibidores selectivos de jak1

Info

Publication number
CO2019007888A2
CO2019007888A2 CONC2019/0007888A CO2019007888A CO2019007888A2 CO 2019007888 A2 CO2019007888 A2 CO 2019007888A2 CO 2019007888 A CO2019007888 A CO 2019007888A CO 2019007888 A2 CO2019007888 A2 CO 2019007888A2
Authority
CO
Colombia
Prior art keywords
selective inhibitors
jak1 selective
compounds
formula
disclosed
Prior art date
Application number
CONC2019/0007888A
Other languages
English (en)
Inventor
Karl Magnus Nilsson
Annika Birgitta Margareta Åstrand
Anna Ingrid Kristina Berggren
Johan R Johansson
Matti Juhani Lepistö
Sameer Pralhad Kawatkar
Qibin Su
Jason Grant Kettle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2019007888A2 publication Critical patent/CO2019007888A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

Se desvelan en el presente documento compuestos de Fórmula (I), y sales farmacéuticamente aceptables de los mismos, en la que R1-R8 tienen cualquiera de los significados definidos en el presente documento. Además, se desvelan composiciones farmacéuticas que comprenden compuestos de Fórmula (I) y métodos de uso de los mismos.
CONC2019/0007888A 2017-01-17 2019-07-23 Inhibidores selectivos de jak1 CO2019007888A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762447057P 2017-01-17 2017-01-17
PCT/EP2018/051038 WO2018134213A1 (en) 2017-01-17 2018-01-16 Jak1 selective inhibitors

Publications (1)

Publication Number Publication Date
CO2019007888A2 true CO2019007888A2 (es) 2019-07-31

Family

ID=61024756

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0007888A CO2019007888A2 (es) 2017-01-17 2019-07-23 Inhibidores selectivos de jak1

Country Status (37)

Country Link
US (2) US10961228B2 (es)
EP (2) EP3571192B1 (es)
JP (3) JP6986086B2 (es)
KR (2) KR102659213B1 (es)
CN (2) CN110461830B (es)
AR (1) AR110753A1 (es)
AU (1) AU2018209667B2 (es)
BR (1) BR112019014526A2 (es)
CA (1) CA3049175A1 (es)
CL (1) CL2019001993A1 (es)
CO (1) CO2019007888A2 (es)
CR (1) CR20190332A (es)
DK (1) DK3571192T3 (es)
DO (1) DOP2019000184A (es)
EA (1) EA037067B1 (es)
EC (1) ECSP19051352A (es)
ES (1) ES2938648T3 (es)
FI (1) FI3571192T3 (es)
HR (1) HRP20230069T1 (es)
HU (1) HUE061064T2 (es)
IL (1) IL267851B (es)
JO (1) JOP20190174B1 (es)
LT (1) LT3571192T (es)
MA (1) MA47301B1 (es)
MX (2) MX2019008435A (es)
NI (1) NI201900077A (es)
PE (1) PE20191108A1 (es)
PH (1) PH12019501639A1 (es)
PL (1) PL3571192T3 (es)
PT (1) PT3571192T (es)
RS (1) RS63981B1 (es)
SG (1) SG11201906222WA (es)
SI (1) SI3571192T1 (es)
TW (1) TWI753089B (es)
UA (1) UA124246C2 (es)
WO (1) WO2018134213A1 (es)
ZA (1) ZA201906875B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018209667B2 (en) * 2017-01-17 2020-05-07 Astrazeneca Ab JAK1 selective inhibitors
WO2018139903A1 (ko) 2017-01-26 2018-08-02 한미약품 주식회사 피리미딘 화합물 및 그의 의약 용도
SG11202100240RA (en) 2018-07-18 2021-02-25 Astrazeneca Ab A xinafoate salt of a jak inhibiting compound
KR20210095621A (ko) * 2018-09-21 2021-08-02 상하이 엔노바바이오 파마슈티컬스 씨오 엘티디. 키나아제 억제 활성을 가진 방향족 헤테로고리 화합물
KR20220003537A (ko) 2019-04-19 2022-01-10 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 Jak1 선택적 키나제 억제제
CA3174321A1 (en) * 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Indazole derivatives as inhibitors of sarm1
US20240025884A1 (en) * 2022-07-05 2024-01-25 Dong-A St Co., Ltd. Compounds as gcn2 inhibitors, pharmaceutical compositions and uses thereof
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
CN115974845A (zh) * 2023-01-19 2023-04-18 奥锐特药业股份有限公司 奥希替尼中间体的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070084067A (ko) * 2004-10-13 2007-08-24 와이어쓰 Ｎ-벤젠설포닐 치환 아닐리노-피리미딘 동족체
CN101421250A (zh) * 2006-01-30 2009-04-29 埃克塞里艾克西斯公司 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物
WO2009046416A1 (en) * 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
MX347851B (es) 2010-03-10 2017-05-16 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
CN103209695A (zh) * 2010-09-15 2013-07-17 弗·哈夫曼-拉罗切有限公司 氮杂苯并噻唑化合物、组合物及应用方法
WO2015061665A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
EP4219482A1 (en) * 2015-09-25 2023-08-02 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Compounds and methods for inhibiting jak
AU2018209667B2 (en) * 2017-01-17 2020-05-07 Astrazeneca Ab JAK1 selective inhibitors

Also Published As

Publication number Publication date
ECSP19051352A (es) 2019-07-31
JP2022043059A (ja) 2022-03-15
US20190367490A1 (en) 2019-12-05
US11897869B2 (en) 2024-02-13
HUE061064T2 (hu) 2023-05-28
UA124246C2 (uk) 2021-08-11
MX2022002976A (es) 2022-04-06
CR20190332A (es) 2019-09-13
ZA201906875B (en) 2021-05-26
MX2019008435A (es) 2019-09-09
FI3571192T3 (fi) 2023-03-06
AR110753A1 (es) 2019-05-02
PH12019501639A1 (en) 2020-07-06
CA3049175A1 (en) 2018-07-26
TWI753089B (zh) 2022-01-21
BR112019014526A2 (pt) 2020-02-27
DOP2019000184A (es) 2019-08-15
KR20190104215A (ko) 2019-09-06
CN110461830B (zh) 2022-11-01
JOP20190174B1 (ar) 2023-09-17
KR102585048B1 (ko) 2023-10-05
IL267851B (en) 2021-08-31
LT3571192T (lt) 2023-02-27
KR102659213B1 (ko) 2024-04-18
MA47301B1 (fr) 2023-02-28
KR20230141938A (ko) 2023-10-10
JP2020506171A (ja) 2020-02-27
ES2938648T3 (es) 2023-04-13
JP7394820B2 (ja) 2023-12-08
AU2018209667A1 (en) 2019-08-22
NI201900077A (es) 2020-03-18
SG11201906222WA (en) 2019-08-27
CN115925693A (zh) 2023-04-07
PT3571192T (pt) 2023-02-21
DK3571192T3 (da) 2023-02-06
RS63981B1 (sr) 2023-03-31
JP2024010041A (ja) 2024-01-23
SI3571192T1 (sl) 2023-03-31
EP3571192A1 (en) 2019-11-27
PL3571192T3 (pl) 2023-03-20
JOP20190174A1 (ar) 2019-07-14
TW201838984A (zh) 2018-11-01
JP6986086B2 (ja) 2021-12-22
PE20191108A1 (es) 2019-08-26
WO2018134213A1 (en) 2018-07-26
US10961228B2 (en) 2021-03-30
AU2018209667B2 (en) 2020-05-07
CN110461830A (zh) 2019-11-15
EA037067B1 (ru) 2021-02-02
EA201991700A1 (ru) 2020-01-28
EP3571192B1 (en) 2022-11-30
EP4219470A1 (en) 2023-08-02
IL267851A (en) 2019-09-26
MA47301A (fr) 2019-11-27
HRP20230069T1 (hr) 2023-03-17
US20210188821A1 (en) 2021-06-24
CL2019001993A1 (es) 2019-12-27

Similar Documents

Publication Publication Date Title
CO2019007888A2 (es) Inhibidores selectivos de jak1
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
CO2020007244A2 (es) Inhibidores de kras g12c
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
UY37205A (es) Inhibidores de bromodominios
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
DOP2015000170A (es) Compuestos químicos
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CU20130124A7 (es) Derivados de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritmia
UY36958A (es) Compuestos para administración intracelular
ECSP13012372A (es) Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
UY36464A (es) Compuestos de quinazolina
UY35348A (es) Derivados de carbazol inhibidores del bromodominio y composiciones que los contienen
UY34430A (es) 18-metil-6,7-metilen-3-oxo-17-pregn-4-en-21,17bcarbolactona, preparados farmacéuticos que contienen los compuestos mencionados y su uso en la terapia de la endometriosis.